X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4377) 4377
Publication (351) 351
Book Review (76) 76
Book Chapter (52) 52
Magazine Article (18) 18
Dissertation (15) 15
Conference Proceeding (11) 11
Data Set (3) 3
Government Document (2) 2
Journal / eJournal (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
memantine (3060) 3060
humans (1915) 1915
index medicus (1606) 1606
male (1383) 1383
animals (1320) 1320
memantine - therapeutic use (1135) 1135
alzheimer's disease (1066) 1066
neurosciences (1050) 1050
pharmacology & pharmacy (914) 914
female (883) 883
memantine - pharmacology (882) 882
dementia (828) 828
alzheimer disease - drug therapy (780) 780
rats (751) 751
aged (664) 664
receptors, n-methyl-d-aspartate - antagonists & inhibitors (662) 662
psychiatry (625) 625
clinical neurology (592) 592
alzheimers-disease (558) 558
donepezil (541) 541
glutamate (528) 528
excitatory amino acid antagonists - therapeutic use (514) 514
excitatory amino acid antagonists - pharmacology (495) 495
cholinesterase inhibitors - therapeutic use (468) 468
double-blind (463) 463
treatment outcome (397) 397
mice (390) 390
middle aged (384) 384
methyl aspartate (352) 352
dose-response relationship, drug (344) 344
drug therapy (335) 335
aged, 80 and over (319) 319
memantine - administration & dosage (316) 316
brain (305) 305
analysis (300) 300
rivastigmine (297) 297
adult (286) 286
receptors, n-methyl-d-aspartate - metabolism (281) 281
cholinesterase inhibitors (278) 278
moderate (277) 277
geriatrics & gerontology (274) 274
efficacy (271) 271
nmda receptor (271) 271
rats, sprague-dawley (270) 270
neurology (269) 269
memantine - adverse effects (249) 249
disease models, animal (238) 238
double-blind method (236) 236
neurons (236) 236
galantamine (227) 227
amantadine (223) 223
nervous system agents (223) 223
neuroprotection (221) 221
alzheimers disease (219) 219
memory (215) 215
dementia - drug therapy (211) 211
dopamine agents - therapeutic use (210) 210
rats, wistar (210) 210
article (209) 209
placebo-controlled trial (205) 205
nootropic agents - therapeutic use (204) 204
drug therapy, combination (202) 202
clinical trials (198) 198
care and treatment (197) 197
neurons - drug effects (197) 197
time factors (197) 197
piperidines - therapeutic use (192) 192
cholinesterase-inhibitors (190) 190
indans - therapeutic use (189) 189
research (189) 189
cognition (179) 179
neuropsychological tests (177) 177
drugs (176) 176
nmda (176) 176
alzheimer’s disease (170) 170
neuroprotective agents - pharmacology (169) 169
nmda receptor antagonist (169) 169
neurodegenerative diseases (165) 165
brain - drug effects (161) 161
severity of illness index (158) 158
glutamic acid receptors (156) 156
biochemistry & molecular biology (153) 153
long-term potentiation (153) 153
cognitive ability (152) 152
excitotoxicity (152) 152
dizocilpine maleate - pharmacology (151) 151
excitatory amino acid antagonists - administration & dosage (149) 149
medicine, general & internal (149) 149
activities of daily living (147) 147
n-methyl-d-aspartic acid receptors (147) 147
cells, cultured (146) 146
hippocampus (146) 146
controlled-trial (145) 145
rat (144) 144
mk-801 (143) 143
alzheimer disease - psychology (141) 141
alzheimer disease (140) 140
neuroprotective agents - therapeutic use (140) 140
nmda receptors (140) 140
cognition disorders - drug therapy (137) 137
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4017) 4017
German (146) 146
Spanish (75) 75
Russian (67) 67
French (36) 36
Japanese (28) 28
Chinese (17) 17
Polish (12) 12
Portuguese (10) 10
Dutch (9) 9
Korean (8) 8
Persian (7) 7
Czech (6) 6
Turkish (6) 6
Italian (5) 5
Danish (4) 4
Norwegian (2) 2
Serbian (2) 2
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Romanian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 10, pp. 893 - 903
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 02/2018, Volume 28, Issue 4, pp. 689 - 693
Journal Article
ACS Chemical Neuroscience, ISSN 1948-7193, 09/2017, Volume 8, Issue 9, pp. 1823 - 1829
Journal Article
Journal Article
CNS Drugs, ISSN 1172-7047, 06/2013, Volume 27, Issue 6, pp. 469 - 478
Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer's disease (AD). This study evaluated the efficacy,... 
DEMENTIA | PSYCHIATRY | PERFORMANCE | BEHAVIORAL SYMPTOMS | COGNITIVE IMPAIRMENT | PSYCHOLOGICAL SYMPTOMS | CLINICAL NEUROLOGY | NEUROPSYCHIATRIC INVENTORY | SPANISH VERSION | DONEPEZIL | COST | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | Excitatory Amino Acid Antagonists - therapeutic use | Excitatory Amino Acid Antagonists - pharmacokinetics | United States | Humans | Male | Alzheimer Disease - diagnosis | Dose-Response Relationship, Drug | Female | Drug Therapy, Combination | Excitatory Amino Acid Antagonists - adverse effects | Memantine - administration & dosage | Alzheimer Disease - psychology | Severity of Illness Index | Memantine - pharmacokinetics | Argentina | Double-Blind Method | Drug Administration Schedule | Alzheimer Disease - drug therapy | Excitatory Amino Acid Antagonists - administration & dosage | Treatment Outcome | Alzheimer Disease - enzymology | Cholinesterase Inhibitors - administration & dosage | Cholinesterase Inhibitors - adverse effects | Mexico | Aged | Cholinesterase Inhibitors - therapeutic use | Memantine - therapeutic use | Delayed-Action Preparations | Memantine - adverse effects | Dosage and administration | Research | Drug therapy | Alzheimer's disease | Cholinesterase inhibitors | Studies | Blister packs | Nuclear magnetic resonance--NMR | Laboratories | Older people | Compensation | Clinical trials | Clinical medicine | Pharmaceutical industry | Drug dosages | Patients
Journal Article
Journal Article